A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Authors

  • Abbas Hajifathali Department of Bone Marrow Transplant, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Ali Tafazoli Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences School of Pharmacy, Tehran, Iran
  • Mahshid Mehdizadeh Department of Bone Marrow Transplant, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Maria Tavakoli Ardakani
  • Simin Dadashzadeg Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti Medical University, Tehran, Iran
Abstract:

Objectives: Graft versus host disease (GVHD) is a life threatening reaction in the stem cell transplantation process. Nowadays Cyclosporine is the most commonly utilized agent for GVHD prophylaxis and it has a major role in successful transplantation. Cyclosporine has been applied for many years in this field but it could be stated that currently no general consensus is available for its optimal method of administration. Conditions related to cyclosporine administration and possible related adverse reactions observed closely in our patients with the aim of constructing a comprehensive practice guideline in the future. Patients and Methods: Allogeneic stem cell transplant recipients who have been taking cyclosporine were monitored during and after their hospitalization while recording all observations on predefined questionnaires on the basis of periodic clinical and laboratory examinations for a 16 month period. Results: Mean recorded duration of infusions was 1.44 ± 0.68 h and by twice daily administration, means intravenous and oral dose was 101.85 ± 22.03 mg and 219.28 ± 63.9 mg, respectively. A mean CsA trough level after about 12 h of specified unique doses was 223 ± 65 ng/mL. We found hypertension, nephrotoxicity, neurotoxicity, hypertension, and dyslipidemia in about 14, 20, 48, and 94 percent of patients. Conclusions: This study proposed that permanent guidance of healthcare team according to a fixed and standard method of cyclosporine administration routine with using efficient facilities and protocols would be helpful considerably for an optimal pharmacotherapy.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

a 16 month survey of cyclosporine utilization evaluation in allogeneic hematopoietic stem cell transplant recipients

objectives: graft versus host disease (gvhd) is a life threatening reaction in the stem cell transplantation process. nowadays cyclosporine is the most commonly utilized agent for gvhd prophylaxis and it has a major role in successful transplantation. cyclosporine has been applied for many years in this field but it could be stated that currently no general consensus is available for its optima...

full text

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Allogeneic hematopoietic stem cell transplantation (AHSCT) is a major method of treatmentfor different hematologic and congenital disease. Graft versus host disease (GvHD) is a lifethreateningadverse effect of AHSCT. Cyclosporine is the most important and common agentfor GvHD prophylaxis. Because of variable and unpredictable pharmacokinetics of cyclosporinethat produces...

full text

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Allogeneic hematopoietic stem cell transplantation (AHSCT) is a major method of treatmentfor different hematologic and congenital disease. Graft versus host disease (GvHD) is a lifethreateningadverse effect of AHSCT. Cyclosporine is the most important and common agentfor GvHD prophylaxis. Because of variable and unpredictable pharmacokinetics of cyclosporinethat produces...

full text

allogeneic hematopoietic progenitor cell transplant recipients

From the Department of Transfusion Medicine, the Department of Clinical Immunology, and the Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital at Huddinge, Stockholm, Sweden. Address reprint requests to: Beatrice Diedrich, MD, Transfusion Medicine, C2 66, Karolinska University Hospital at Huddinge, 141 86 Stockholm, Sweden; e-mail: beatrice.diedrich@ karolinska.se. ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 15  issue 1

pages  331- 339

publication date 2016-02-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023